Edition:
United Kingdom

Bioverativ Inc (BIVV.OQ)

BIVV.OQ on NASDAQ Stock Exchange Global Select Market

63.00USD
5:45pm GMT
Change (% chg)

$-0.87 (-1.36%)
Prev Close
$63.87
Open
$64.15
Day's High
$64.30
Day's Low
$62.69
Volume
142,269
Avg. Vol
384,776
52-wk High
$65.05
52-wk Low
$41.21

Select another date:

Mon, Dec 11 2017

BRIEF-Bioverativ’s BIVV009 achieves positive results in Phase 1B CAgD patients

* BIOVERATIV’S INVESTIGATIONAL BIVV009 DEMONSTRATES SAFETY, TOLERABILITY AND EFFICACY IN PHASE 1B CLINICAL TRIAL IN COLD AGGLUTININ DISEASE (CAGD) PATIENTS

BRIEF-Bioverativ reports Q3 earnings per share $0.63

* Q3 revenue $291.6 million versus i/b/e/s view $285.5 million

BRIEF-Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400

* Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400 -- a gene-edited cell therapy candidate -- to treat beta-thalassemia

BRIEF-Bioverativ and Bicycle Therapeutics enter into strategic research collaboration

* Bioverativ and Bicycle Therapeutics enter into strategic research collaboration to develop therapies for haemophilia and sickle cell disease

BRIEF-Bioverativ reports Q2 GAAP earnings per share $0.71

* Q2 earnings per share view $0.71 -- Thomson Reuters I/B/E/S

BRIEF-Valueact Capital Management LLC reports 3.8 pct stake in Bioverativ Inc as of July 13 - SEC filing

* Valueact Capital Management LLC reports 3.8 percent stake in Bioverativ Inc as of July 13 versus 7.5 percent stake as of Feb 28 - SEC filing Source text:(http://bit.ly/2u29MGC) Further company coverage:

Select another date: